beta
/658 KAN-001, a defined live biotherapeutic product (LBP) for NSCLC, enhances ICI response in preclinical models and demonstrates manufacturing consistency and strain-resolved viability
Abstract

Abstract N/A

RelatedView All
Authors 1View All
CitationsView All
Citing-
Cited By-